4-(tributylstannyl)pyrazole | 172282-32-5

• 分子结构分类: 有机化合物 - 有机金属化合物 - 金属芳基
• 英文名称: 4-(tributylstannyl)pyrazole
• 英文别名: 4-Tributylstannylpyrazole；tributyl(1H-pyrazol-4-yl)stannane
• CAS: 172282-32-5
• 化学式: C₁₅H₃₀N₂Sn
• 分子量: 357.127
• InChiKey: JPWUNFPCMJPDPQ-UHFFFAOYSA-N

物化性质

• 沸点：
  394.9±34.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.47
• 重原子数：
  18
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(tributylstannyl)pyrazole 、 5,11-dihydro-11-ethyl-5-methyl-2-<<(trifluoromethyl)-sulfonyl>oxy>-6H-dipyrido<3,2-b:2',3'-e><1,4>diazepin-6-one 在 bis-triphenylphosphine-palladium(II) chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以39%的产率得到5,11-dihydro-11-ethyl-5-methyl-2-(4-pyrazolyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
  参考文献：
  名称：

  Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes

  摘要：

  The major cause of viral resistance to the potent human immunodeficiency virus type 1 reverse transcriptase (RT) inhibitor nevirapine is the mutation substituting cysteine for tyrosine-181 in RT (Y181C RT), An evaluation, against Y181C RT, of previously described analogs of nevirapine revealed that the 2-chlorodipyridodiazepinone 16 is an effective inhibitor of this mutant enzyme. The detailed examination of the structure-activity relationship of 2-substituted dipyridodiazepinones presented below shows that combined activity against the wildtype and Y181C enzymes is achieved with aryl substituents at the 2-position of the tricyclic ring system. In addition, the substitution pattern at C-4, N-5, and N-11 of the dipyridodiazepinone ring system optimum for inhibition of both wild-type and Y181C RT is no longer the 4-methyl-11-cyclopropyl substitution preferred against the wild-type enzyme but rather the 5-methyl-11-ethyl (or 11-cyclopropyl) pattern. The more potent 8-substituted dipyridodiazepinones were evaluated against mutant RT enzymes (L100I RT, K103N RT, P236L RT, and E138K RT) that confer resistance to other non-nucleoside RT inhibitors, and compounds 42, 62, and 67, with pyrrolyl, aminophenyl, and aminopyridyl substituents, respectively, at the 2-position, were found to be effective inhibitors of these mutant enzymes also.

  DOI：

  10.1021/jm00024a010
• 作为产物：
  描述：

  4-碘吡唑 、 三丁基氯化锡 在 叔丁基锂 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 生成 4-(tributylstannyl)pyrazole
  参考文献：
  名称：

  2-heteroaryl-5,11-dihydro-6H-dipyrido\x9b3,2-B:2',3'-E!\x9b1,4!diazepines and

  摘要：

  治疗HIV-1感染的新化合物。这些是具有以下结构的2-杂环-5,11-二氢-6H-二吡啶\x9b3,2-b:2',3'-e!\x9b1,4!二氮杂环化合物，其中Z为氧、硫、.dbd.NCN或.dbd.NOR.sup.10，Ar为以下结构的基团I、II、III、IV或V。

  公开号：

  US05837704A1

文献信息

• 2-Aryl-5,11-dihydro-6H-dipyrido 3,2-b:2',3'-e 1,4 diazepines and their use for the preparation of pharmaceutical compositions for the treatment of HIV infection
  申请人：BOEHRINGER INGELHEIM PHARMACEUTICALS INC.

  公开号：EP0791594A2

  公开（公告）日：1997-08-27

  Disclosed are novel 2-aryl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepines. These are useful in the of HIV infection. Exemplary compounds are: 8-Ethyl-1-methyl-10-(4-pyrazolyl)imidazo[2',3':6,5]dipyrido[3,2-b:2',3'-e][1,4]diazepine; 8-c-Propyl-1-methyl-10-(4-pyrazolyl)imidazo[2',3':6,5]dipyrido[3,2-b:2',3'-e][1,4]diazepine; 8-Ethyl-12-methyl-10-(4-pyrazolyl)imidazo[2',3':6,5]dipyrido[3,2-b:2',3'-e][1,4]diazepine; and, 8-c-Propyl-12-methyl-10-(4-pyrazolyl)imidazo[2',3':6,5]dipyrido[3,2-b:2',3'-e][1,4]diazepine.

  本发明涉及新型的2-芳基-5,11-二氢-6H-二吡咯[3,2-b:2',3'-e][1,4]二氮杂环。这些化合物在治疗HIV感染方面具有用途。其中一些典型的化合物包括：8-乙基-1-甲基-10-(4-吡唑基)咪唑并[2',3':6,5]二吡咯[3,2-b:2',3'-e][1,4]二氮杂环；8-c-丙基-1-甲基-10-(4-吡唑基)咪唑并[2',3':6,5]二吡咯[3,2-b:2',3'-e][1,4]二氮杂环；8-乙基-12-甲基-10-(4-吡唑基)咪唑并[2',3':6,5]二吡咯[3,2-b:2',3'-e][1,4]二氮杂环；以及8-c-丙基-12-甲基-10-(4-吡唑基)咪唑并[2',3':6,5]二吡咯[3,2-b:2',3'-e][1,4]二氮杂环。
• 5,11-dihydro-6H-dipyrido\x9b3,2-b:2',3'-e!azepine-6-ones and their use in
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US05908841A1

  公开（公告）日：1999-06-01

  There are disclosed compounds of the formula 1 ##STR1## wherein X is an oxygen atom or nothing and R1, R2 and R3 are as defined in the specification, useful in the prevention or treatment of HIV infection.

  公开了一些化合物的公式1 ##STR1## 其中X是氧原子或空，R1、R2和R3如规范中定义的那样，可用于预防或治疗HIV感染。
• Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors
  作者：Aiko Nitta、Hideaki Fujii、Satoshi Sakami、Mikiya Satoh、Junko Nakaki、Shiho Satoh、Hiroki Kumagai、Hideki Kawai

  DOI：10.1016/j.bmcl.2012.09.099

  日期：2012.12

  A series of novel 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides were investigated as dipeptidyl peptidase IV (DPP-4) inhibitors. Introduction of a 4-phenylthiazol-2-yl group showed highly potent DPP-4 inhibitory activity. Among various derivatives, (3R)-3-amino-N-(4-(4-phenylthiazol-2-yl)-tetrahydro-2H-thiopyran-4-yl)-4-(2,4,5-trifluorophenyl)butanamide 1,1-dioxide (30) reduced blood glucose excursion in an oral glucose tolerance test by oral administration. (C) 2012 Elsevier Ltd. All rights reserved.
• 2-heteroaryl-5,11-dihydro-6H-dipyrido\x9b3,2-B:2',3'-E!\x9b1,4!diazepines and
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US05837704A1

  公开（公告）日：1998-11-17

  Novel compounds for the treatment of HIV-1 infection. These are 2-heteroary-5,11-dihydro-6H-dipyrido\x9b3,2-b:2',3'-e!\x9b1,4!diazepines of the formula ##STR1## wherein Z is oxygen, sulfur, .dbd.NCN or .dbd.NOR.sup.10 and Ar is a group of the formula I, II, III, IV or V ##STR2##

  治疗HIV-1感染的新化合物。这些是具有以下结构的2-杂环-5,11-二氢-6H-二吡啶\x9b3,2-b:2',3'-e!\x9b1,4!二氮杂环化合物，其中Z为氧、硫、.dbd.NCN或.dbd.NOR.sup.10，Ar为以下结构的基团I、II、III、IV或V。
• Novel Non-nucleoside Inhibitors of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzymes
  作者：John R. Proudfoot、Karl D. Hargrave、Suresh R. Kapadia、Usha R. Patel、Karl G. Grozinger、Daniel W. McNeil、Ernest Cullen、Mario Cardozo、Liang Tong

  DOI：10.1021/jm00024a010

  日期：1995.11

  The major cause of viral resistance to the potent human immunodeficiency virus type 1 reverse transcriptase (RT) inhibitor nevirapine is the mutation substituting cysteine for tyrosine-181 in RT (Y181C RT), An evaluation, against Y181C RT, of previously described analogs of nevirapine revealed that the 2-chlorodipyridodiazepinone 16 is an effective inhibitor of this mutant enzyme. The detailed examination of the structure-activity relationship of 2-substituted dipyridodiazepinones presented below shows that combined activity against the wildtype and Y181C enzymes is achieved with aryl substituents at the 2-position of the tricyclic ring system. In addition, the substitution pattern at C-4, N-5, and N-11 of the dipyridodiazepinone ring system optimum for inhibition of both wild-type and Y181C RT is no longer the 4-methyl-11-cyclopropyl substitution preferred against the wild-type enzyme but rather the 5-methyl-11-ethyl (or 11-cyclopropyl) pattern. The more potent 8-substituted dipyridodiazepinones were evaluated against mutant RT enzymes (L100I RT, K103N RT, P236L RT, and E138K RT) that confer resistance to other non-nucleoside RT inhibitors, and compounds 42, 62, and 67, with pyrrolyl, aminophenyl, and aminopyridyl substituents, respectively, at the 2-position, were found to be effective inhibitors of these mutant enzymes also.